Immupharma PLC Holding(s) in Company (3035R)
08 March 2016 - 2:31AM
UK Regulatory
TIDMIMM
RNS Number : 3035R
Immupharma PLC
07 March 2016
RNS : FOR IMMEDIATE RELEASE 7 MARCH 2016
ImmuPharma PLC
TR1 NOTIFICATION OF MAJOR INTEREST BY LANSTEAD
ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the
specialist drug discovery and development company, confirms that it
has received a TR-1 by Lanstead Capital LP ("Lanstead") confirming
its increased holding in ImmuPharma to 17,893,456 Ordinary
Shares.
This follows on from the announcement on 1 March 2016 that
ImmuPharma has received advance assurance from HM Revenue and
Customs of EIS and VCT qualifying status and the issue and
allotment of 2,856,539 new Ordinary Shares of 10 pence each.
ImmuPharma now has a total of 121,781,219 Ordinary Shares of 10
pence each in issue which takes Lanstead's current position in the
Company to 14.69%
Full disclosure of the TR1 is shown below:
1: NOTIFICATION OF MAJOR INTEREST IN SHARES
1. Identity of the issuer or
the underlying issuer of existing Immupharma plc
shares to which voting rights
are attached:
------------------------------------------------------------- --------------------------------------------------
2. Reason for the notification (please tick the appropriate
box or boxes):
-----------------------------------------------------------------------------------------------------------------
An acquisition or disposal of voting rights x
---------------------------------------------------------------------------------------------------- -----------
An acquisition or disposal of qualifying financial
instruments which may result in the acquisition
of shares already issued to which voting rights
are attached
---------------------------------------------------------------------------------------------------- -----------
An acquisition or disposal of instruments with
similar economic effect to qualifying financial
instruments
---------------------------------------------------------------------------------------------------- -----------
An event changing the breakdown of voting rights
---------------------------------------------------------------------------------------------------- -----------
Other (please specify): The placement by ImmuPharma x
PLC of 2,856,539 new ordinary shares
---------------------------------------------------------------------------------------------------- -----------
3. Full name of person(s)
subject to the notification Lanstead Capital LP
obligation:
---------------------------------------------- -----------------------------------------------------------------
4. Full name of shareholder(s)
(if different from 3.):
---------------------------------------------- -----------------------------------------------------------------
5. Date of the transaction
and date on 4 March 2016
which the threshold is crossed
or reached:
---------------------------------------------- -----------------------------------------------------------------
6. Date on which issuer notified: 4 March 2016
---------------------------------------------- -----------------------------------------------------------------
7. Threshold(s) that is/are
crossed or reached: 15%
---------------------------------------------- -----------------------------------------------------------------
8. Notified details:
-----------------------------------------------------------------------------------------------------------------
A: Voting rights attached to shares
-----------------------------------------------------------------------------------------------------------------
Class/type Situation previous Resulting situation after the
of to the triggering triggering transaction
shares transaction
if possible
using the
ISIN CODE
---------------- ---------------------------- -----------------------------------------------------------------
Number Number Number Number of voting % of voting
of of Voting of shares rights rights
Shares Rights
---------------- ------------- ------------- ------------- -------------------------- ----------------------
Direct Direct Indirect Direct Indirect
---------------- ------------- ------------- ------------- ------------- ----------- --------- -----------
GB0033711010 17,872,341 17,872,341 17,893,456 17,893,456 14.69%
---------------- ------------- ------------- ------------- ------------- ----------- --------- -----------
B: Qualifying Financial Instruments
------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
------------------------------------------------------------------------------------
Type of financial Expiration Exercise/ Number of voting % of voting
instrument date Conversion rights that rights
Period may be acquired
if the instrument
is exercised/
converted.
---------------------- ----------- ------------ ------------------- ------------
N/A
---------------------- ----------- ------------ ------------------- ------------
C: Financial Instruments with similar economic effect
to Qualifying Financial Instruments
------------------------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
------------------------------------------------------------------------------------------------------
Exercise/
Type of financial Exercise Expiration Conversion Number of voting % of voting
instrument price date period rights rights
instrument refers
to
-------------------- ----------- ------------- ------------ -------------------- ----------------
Nominal Delta
-------------------- ----------- ------------- ------------ -------------------- -------- ------
N/A
-------------------- ----------- ------------- ------------ -------------------- -------- ------
Total (A+B+C)
------------------------------------------------------
Number of voting rights Percentage of voting rights
------------------------ ----------------------------
17,893,456 14.69%
------------------------ ----------------------------
9. Chain of controlled undertakings through which
the voting rights and/or the financial instruments
are effectively held, if applicable:
----------------------------------------------------
N/A
----------------------------------------------------
Proxy Voting:
----------------------------------------
10. Name of the proxy holder:
--------------------------------------
11. Number of voting rights proxy
holder will cease to hold:
--------------------------------------
12. Date on which proxy holder will
cease to hold voting rights:
--------------------------------------
13. Additional information:
------------------------------- ----------------------------------
14. Contact name: Lisa De Vargas, Lanstead Partners
Limited
------------------------------- ----------------------------------
15. Contact telephone number: +1 (801) 895-3700
------------------------------- ----------------------------------
-Ends-
For further information please
contact:
+ 44 (0) 20
ImmuPharma plc (www.immupharma.org) 7152 4080
Tim McCarthy, Chairman
Lisa Baderoon, Head of Investor
Relations + 44 (0) 7721
Twitter: @immupharma 413496
Panmure, Gordon & Co., NOMAD & +44 (0) 20 7886
Broker 2500
Fred Walsh, Duncan Monteith, Corporate
Finance
Charles Leigh-Pemberton, Corporate
Broking
Notes to Editors
ImmuPharma PLC
ImmuPharma is a pharmaceutical development company listed since
2006 on AIM of the London Stock Exchange (LSE:IMM), focusing on
developing novel medicines with high sales potential in specialist
markets with serious unmet need. ImmuPharma is led by a
commercially focused Board and management team with extensive
experience.
ImmuPharma announced on 1 March 2016 the successful completion
of a GBP8.4 million fund raise, comprising a Placing and
Subscription together with confirmation of EIS and VCT qualifying
status. Monies raised will principally be used to complete the
pivotal Phase III trial of Lupuzor(TM). Following the issue of the
New Ordinary Shares referred to above, ImmuPharma will have
121,781,219 ordinary shares of 10 pence each (the "Ordinary
Shares") in issue.
Lupuzor(TM)
March 07, 2016 10:31 ET (15:31 GMT)
Lupuzor(TM) (also referred to as forigerimod, rigerimod,
IPP-201101 or P140 is ImmuPharma's lead compound and a potential
treatment for lupus (or Systemic Lupus Erythematosus), a chronic,
potentially life-threatening auto-immune disease. Lupuzor(TM) has a
novel mechanism of action aimed at modulating the body's immune
system so that it does not attack healthy cells, and avoids causing
adverse side effects. It has the potential to halt the progression
of the disease in a substantial proportion of patients.
Lupuzor(TM) has been granted Fast Track status by the US FDA and
approval to start Phase III under Special Protocol Assessment
(SPA). This SPA was subsequently amended due to its strong safety
and efficacy profile to allow for a reduced number of patients in
the pivotal Phase III trial thereby reducing the projected cost and
time of development considerably.
The pivotal Phase III clinical study is entitled "A 52-Week,
Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study
to Evaluate the Efficacy and Safety of a 200-mcg Dose of IPP-201101
Plus Standard of Care in Patients With Systemic Lupus
Erythematosus". It is a pivotal study designed to demonstrate the
safety and efficacy of IPP-201101 and as a last step prior to the
filing of the drug for approval with the US Food & Drug
Administration ("FDA") and the European Medicines Agency ("EMA").
For more information please visit:
www.ClinicalTrials.gov/lupuzor
Commercial Opportunity
There are an estimated five million people globally suffering
from Lupus, with approximately 1.5 million patients in the US,
Europe and Japan (Source: Lupus Foundation of America). Current
'standard of care' treatments, including steroids and
immunosuppressants, can potentially have either serious side
effects for patients or limited effectiveness, with over 60% of
patients not adequately treated. GSK's Benlysta is the first Lupus
drug approved in over 50 years and paves the path to market for
Lupuzor(TM). Based on conservative estimates, and taking into
account that Benlysta is priced currently at approximately $35,000
per patient per year, Lupuzor(TM) would be entering a market with
the potential for multi-billion dollar sales. For more information
on Lupuzor(TM) please visit: www.lupuzor.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
HOLEDLFBQXFLBBD
(END) Dow Jones Newswires
March 07, 2016 10:31 ET (15:31 GMT)
Immupharma (LSE:IMM)
Historical Stock Chart
From Apr 2024 to May 2024
Immupharma (LSE:IMM)
Historical Stock Chart
From May 2023 to May 2024